Loading...
HomeMy WebLinkAboutDEQ-CFW_00074352DuPont, DWM and DWQ Meeting Summary August 26, 2010 Attendees: DWM: Linda Culpepper, Larry Stanley, Carl Utterback, Bud McCarty, Vance Jackson, Kathy Akroyd DWQ: Connie Brower, Sandra Moore, Matt Matthews, Belinda Henson, Sergei Chernikov, Tom Belnick DuPont. Michael Johnson, Jenny Lui, John Nash, Jamie Van Buskirk, Jim Hoover, Gary Jepson Purpose of Meeting: To provide an update on DuPont's progress on its USEPA 2010/15 PFOA Stewardship Program commitment; share information on GenX processing aid technology (to replace PFOA); establish a dialogue with NCDENR regarding the use of GenX technology at DuPont Fayetteville Works. DuPont gave an update on the 2010/15 PFOA Stewardship Program, an EPA sponsored program in which companies commit to reduce global facility emissions and product content of PFOA and related chemicals by 95 percent by 2010, and to work toward eliminating emissions and product content by 2015. httr)://www2.duDont.com/PFOA2/en US/pfoa stewardshiD.html http://www.epa.gov/opptintr/pfoa/ PFOA is only manufactured at DuPont's Fayetteville Facility but is used at other places in manufacturing. PFOA is used to make fluoropolymer material (resins and dispersions) that are then used to make products such as Teflon cookware. PFOA is a global contaminant found at low levels in the environment and in the blood of the US general population (average blood level of 5ppb). It is persistent in the environment and remains in people a long time. It has been shown to cause adverse health effects in animals and is suspected to cause adverse health effects in people. DuPont is currently testing a new product called GenX, to replace PFOA. DuPont stated that this new processing aid has a favorable toxicological profile and rapid bio-elimination and that DuPont's planned environmental exposure control technologies will reduce the potential for environmental release and exposure. GenX has been reviewed by USEPA through the Premanufacture Notification process and the USEPA TSCA Office granted DuPont approval to commercially manufacture, process, and distribute GenX under conditions set forth in a Consent Order. DEQ-CFW 00074352 GenX Characteristics: • Low potential for accumulation in the body (elimination in 12-24 hours compared with months for PFOA); • low acute toxicity in mammalian and aquatic testing; • low repeated dose toxicity in mammalian testing; • it is not mutagenic or genotoxic; • it is not a skin sensitizer GenX technology will enable the production of fluoropolymer resins, and end -use articles made from the resin, that contain extremely low to non -detectable residual processing aid content. Goal is to contain the new processing aid within the manufacturing site and to minimize worker exposures through the use of scrubbers, PPE and point source exhaust trucks. DuPont has begun investing in their production facilities, have started customer conversions and expects to meet the 2015 commitment to phase out PFOA. 2 DEQ-CFW 00074353